Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6
 and E7 specific T cell response and lesion condition in subjects who have administered in
 DNA-based therapeutic vaccine.
This is a follow-up study to investigate the change of immunogenicity and lesion condition in
 subjects with cervical intraepithelial neoplasia (CIN) 3 who have enrolled and participated
 GX-188E phase II trial(GX-188E_CIN3_P2).

 Subjects will make visits 7 times for about three years from the last visit of GX-188E phase
 2 trial (GX-188E_CIN3_P2).

 The endpoints are to evaluate the change of immune response, involved lesion and infection
 status compared to that of the final visit in phase 2 trial (GX-188E_CIN3_P2).
Inclusion Criteria:

 -  Those who voluntarily signed informed consent form

 -  The subjects who have participated in phase II trial(GX-188E_CIN3_P2)

 Exclusion Criteria:

 -  The subjects who didn't receive GX-188E DNA vaccine during Phase II trial
 (GX-188E_CIN3_P2)

 -  The subjects, it is difficult to participate in this study continuously

 -  Any other ineligible condition at the discretion of the investigator that would be
 ineligible to participate the study